The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal

Autor: Amit Sokolov, Adi Reches, Sarit Avraham, Benny Almog, Liat Zakar, Foad Azem, Mira Malcov, Sharon Alpern
Rok vydání: 2016
Předmět:
0301 basic medicine
Adult
Ovulation
medicine.medical_specialty
Heterozygote
Oocyte Retrieval
Genetic Counseling
Controlled ovarian hyperstimulation
Fertilization in Vitro
Biology
Primary Ovarian Insufficiency
Cohort Studies
Tertiary Care Centers
03 medical and health sciences
0302 clinical medicine
Ovulation Induction
Trinucleotide Repeats
Biopsy
medicine
Humans
Fertility preservation
Ovarian follicle
Ovarian reserve
Ovarian Reserve
Referral and Consultation
Preimplantation Diagnosis
Retrospective Studies
Gynecology
030219 obstetrics & reproductive medicine
medicine.diagnostic_test
Rehabilitation
Ovary
Obstetrics and Gynecology
Retrospective cohort study
Fertility Agents
Female

medicine.disease
FMR1
Fragile X syndrome
030104 developmental biology
medicine.anatomical_structure
Reproductive Medicine
Fragile X Syndrome
Mutation
Female
Infertility
Female

Gonadotropins
Zdroj: Human reproduction (Oxford, England). 32(7)
ISSN: 1460-2350
Popis: Study question What is the association between the ovarian response and the number of CGG repeats among full mutation and premutation carriers of fragile X (FMR1), undergoing controlled ovarian hyperstimulation (COH) for PGD? Summary answer Ovarian response was normal in full mutation patients but decreased in premutation carriers, although the number of repeats was not statistically significantly associated with the number of oocytes retrieved. What is known already There is inconsistent data in the literature regarding ovarian response in FMR1 carriers. Studies exploring the ovarian response of full mutation patients are lacking. Study design, size, duration Retrospective study, a university affiliated tertiary hospital, IVF unit, PGD referral center. Participants/materials, setting, methods We examined the medical records of all women undergoing fresh IVF-PGD cycles due to fragile X. Data recorded included demography, duration of stimulation, amount of gonadotropins administered, number of dominant follicles, maximal E2 levels and number of oocytes retrieved. Data were analyzed using univariate and multivariate mixed models. P-values Main results and the role of chance Premutation carriers displayed reduced ovarian response, as demonstrated by fewer oocytes retrieved. In contrast, full mutation patients had a normal response. Comparison of premutation carriers and full mutation patients showed: mean oocytes retrieved per cycle (8.4 ± 1.1 versus 14.1 ± 1.7, P = 0.005), lower levels of estradiol (E2; 1756 ± 177, versus 2928 ± 263, P = 0.0004), respectively. There was no significant difference between premutation carriers and full mutation patients in regard to fertilization rate, cleavage rate or biopsy rate. No correlation was found between the number of repeats in the premutation carriers and the number of oocytes retrieved or E2 levels. Age and the type of protocol were the only factors found to be in correlation with the number of the oocyte retrieved (P = 0.037, and P = 0.003, respectively) among the premutation carriers. Similarly, no association was found between the number of repeats and the fertilization rate, cleavage rate or biopsy rate among premutation carriers. Limitations, reasons for caution We had a relatively low number of premutation carriers with >100 repeats, which made it challenging to draw a firm conclusions from this group. Wider implications of the findings Physicians must address the increased risk for reduced ovarian response and primary ovarian insufficiency (POI) among carriers and consider surveillance of ovarian reserve markers. The last, might expedite family plans completion or fertility preservation. Study funding/competing interest(s) None.
Databáze: OpenAIRE